Evotec SE
Company Profile
Business description
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Contact
Essener Bogen 7
22419 Hamburg
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,553
Stocks News & Analysis
stocks
Higher credit stress for big four bank
stocks
The ASX player evolving into a defensive haven
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.00 | 21.20 | -0.23% |
| CAC 40 | 8,331.05 | 94.08 | -1.12% |
| DAX 40 | 24,417.80 | 284.44 | -1.15% |
| Dow JONES (US) | 49,442.56 | 4.87 | -0.01% |
| FTSE 100 | 10,609.08 | 58.55 | -0.55% |
| HKSE | 26,471.86 | 110.79 | 0.42% |
| NASDAQ | 24,404.39 | 64.09 | -0.26% |
| Nikkei 225 | 59,499.84 | 674.95 | 1.15% |
| NZX 50 Index | 12,932.33 | 16.88 | 0.13% |
| S&P 500 | 7,109.14 | 16.92 | -0.24% |
| S&P/ASX 200 | 8,945.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,079.44 | 2.69 | -0.07% |